Travere Therapeutics, Inc. (TVTX) stock
TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$50.24−0.86 (-1.68%)
Close on Nov 18, 2026Market cap $4.74BP/E –Yield –
Travere Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Travere Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$40.46M. For fiscal 2026 it was -$62.82M. The highest annual figure on record is -$24.77M in fiscal 2014.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Dec 31, 2025 | -$62.82M | – |
| FY2025 | Dec 31, 2024 | -$323.83M | – |
| FY2024 | Dec 31, 2023 | -$388.14M | – |
| FY2023 | Dec 31, 2022 | -$319.81M | – |
| FY2022 | Dec 31, 2021 | -$199.43M | – |
| FY2021 | Dec 31, 2020 | -$176.16M | – |
| FY2020 | Dec 31, 2019 | -$137.36M | – |
| FY2019 | Dec 31, 2018 | -$80.04M | – |
| FY2018 | Dec 31, 2017 | -$53.79M | – |
| FY2017 | Dec 31, 2016 | -$58.21M | – |
| FY2016 | Dec 31, 2015 | -$50.75M | – |
| FY2015 | Dec 31, 2014 | -$79.81M | – |
| FY2014 | Dec 31, 2013 | -$24.77M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027 | Jun 30, 2026 | $3.95M | – |
| Q1 FY2027 | Mar 31, 2026 | -$36.92M | – |
| Q4 FY2026 | Dec 31, 2025 | -$32.43M | – |
| Q3 FY2026 | Sep 30, 2025 | $24.93M | – |
| Q2 FY2026 | Jun 30, 2025 | -$12.65M | – |
| Q1 FY2026 | Mar 31, 2025 | -$42.67M | – |
| Q4 FY2025 | Dec 31, 2024 | -$60.74M | – |
| Q3 FY2025 | Sep 30, 2024 | -$56.15M | – |
| Q2 FY2025 | Jun 30, 2024 | -$67.70M | – |
| Q1 FY2025 | Mar 31, 2024 | -$139.24M | – |
| Q4 FY2024 | Dec 31, 2023 | -$94.23M | – |
| Q3 FY2024 | Sep 30, 2023 | -$92.59M | – |
| Q2 FY2024 | Jun 30, 2023 | -$103.95M | – |
| Q1 FY2024 | Mar 31, 2023 | -$97.37M | – |
| Q4 FY2023 | Dec 31, 2022 | -$86.70M | – |
| Q3 FY2023 | Sep 30, 2022 | -$82.60M | – |
| Q2 FY2023 | Jun 30, 2022 | -$78.53M | – |
| Q1 FY2023 | Mar 31, 2022 | -$71.98M | – |
| Q4 FY2022 | Dec 31, 2021 | -$84.85M | – |
| Q3 FY2022 | Sep 30, 2021 | -$31.71M | – |
| Q2 FY2022 | Jun 30, 2021 | -$35.32M | – |
| Q1 FY2022 | Mar 31, 2021 | -$47.55M | – |
| Q4 FY2021 | Dec 31, 2020 | -$118.55M | – |
| Q3 FY2021 | Sep 30, 2020 | -$19.44M | – |
| Q2 FY2021 | Jun 30, 2020 | -$23.11M | – |
| Q1 FY2021 | Mar 31, 2020 | -$15.07M | – |
| Q4 FY2020 | Dec 31, 2019 | -$28.17M | – |
| Q3 FY2020 | Sep 30, 2019 | -$34.44M | – |
| Q2 FY2020 | Jun 30, 2019 | -$36.53M | – |
| Q1 FY2020 | Mar 31, 2019 | -$38.23M | – |
| Q4 FY2019 | Dec 31, 2018 | -$4.99M | – |
| Q3 FY2019 | Sep 30, 2018 | -$35.58M | – |
| Q2 FY2019 | Jun 30, 2018 | -$21.56M | – |
| Q1 FY2019 | Mar 31, 2018 | -$17.91M | – |
| Q4 FY2018 | Dec 31, 2017 | -$15.18M | – |
| Q3 FY2018 | Sep 30, 2017 | -$10.61M | – |
| Q2 FY2018 | Jun 30, 2017 | -$13.60M | – |
| Q1 FY2018 | Mar 31, 2017 | -$14.41M | – |
| Q4 FY2017 | Dec 31, 2016 | -$18.22M | – |
| Q3 FY2017 | Sep 30, 2016 | -$20.37M | – |
See a number that looks wrong?